INT64523

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.33
First Reported 1996
Last Reported 2010
Negated 0
Speculated 0
Reported most in Abstract
Documents 10
Total Number 10
Disease Relevance 2.72
Pain Relevance 7.29

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (Ndp) extracellular region (Ndp) cellular_component (Ndp)
biological_process (Ndp)
Anatomy Link Frequency
ventromedial hypothalamic nucleus 1
Ndp (Rattus norvegicus)
Pain Link Frequency Relevance Heat
headache 19 100.00 Very High Very High Very High
Morphine 24 99.80 Very High Very High Very High
Potency 15 99.24 Very High Very High Very High
melanocortin 1 receptor 6 98.72 Very High Very High Very High
antagonist 14 97.04 Very High Very High Very High
agonist 3 93.64 High High
Antinociceptive 6 90.36 High High
Intracerebroventricular 2 87.28 High High
tolerance 12 86.00 High High
tail-flick 2 85.84 High High
Disease Link Frequency Relevance Heat
Headache 15 100.00 Very High Very High Very High
Obesity 3 88.24 High High
Sprains And Strains 1 85.84 High High
Headache Disorders 4 80.72 Quite High
Hyperalgesia 10 80.40 Quite High
Reperfusion Injury 2 69.92 Quite High
Pain 4 66.60 Quite High
INFLAMMATION 1 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Follow-up disclosed that the symptomatology of NDPH is not unchangeable, since two persons had improvement of their NDPH.
NDPH Binding (improvement) of associated with headache
1) Confidence 0.33 Published 2009 Journal Cephalalgia Section Abstract Doc Link 19830882 Disease Relevance 1.49 Pain Relevance 1.49
Isobolographic analysis revealed antagonistic interaction between NDP-MSH and morphine, and additive interaction between HS014 and morphine combinations.
NDP-MSH Binding (interaction) of associated with morphine
2) Confidence 0.12 Published 2007 Journal Brain Res. Section Abstract Doc Link 17915196 Disease Relevance 0.43 Pain Relevance 2.01
Treatment with NDP-MSH was associated with early and marked increase in interleukin 6 (IL-6) mRNA.
NDP-MSH Binding (associated) of
3) Confidence 0.10 Published 2010 Journal Peptides Section Abstract Doc Link 19799952 Disease Relevance 0.07 Pain Relevance 0.21
Isobolographic analysis revealed antagonistic interaction between NDP-MSH and morphine, and additive interaction between HS014 and morphine combinations.
NDP-MSH Binding (interaction) of associated with morphine
4) Confidence 0.09 Published 2007 Journal Brain Res. Section Abstract Doc Link 17915196 Disease Relevance 0.43 Pain Relevance 2.01
We found that OLETF rats show a reduction in total [125I]NDP-MSH MC receptor binding in the ventromedial hypothalamic nucleus, perhaps reflecting an increased release of MC peptides in this region.
NDP-MSH MC receptor Binding (binding) of in ventromedial hypothalamic nucleus
5) Confidence 0.09 Published 2000 Journal Brain Res. Section Abstract Doc Link 10661510 Disease Relevance 0.31 Pain Relevance 0.13
Substitution of aspartic acid117 and histidine260 by alanine in melanocortin 1 receptor resulted in a 4.75-fold decrease (Ki 4541 +/- 644 nM) and an 11-fold increase (Ki 84.29 +/- 4.53 nM), respectively, in the relative potency of 153N-6 for competitively inhibiting [125I]NDP-MSH binding.
NDP-MSH Binding (binding) of associated with melanocortin 1 receptor and potency
6) Confidence 0.01 Published 1996 Journal Peptides Section Abstract Doc Link 8801544 Disease Relevance 0 Pain Relevance 0.30
The results indicated that 153N-6 peptide can competitively inhibit [125I]NDP-MSH binding from all the receptor subtypes investigated.
NDP-MSH Binding (binding) of
7) Confidence 0.01 Published 1996 Journal Peptides Section Abstract Doc Link 8801544 Disease Relevance 0 Pain Relevance 0.27
Substitution of aspartic acid117 and histidine260 by alanine in melanocortin 1 receptor resulted in a 4.75-fold decrease (Ki 4541 +/- 644 nM) and an 11-fold increase (Ki 84.29 +/- 4.53 nM), respectively, in the relative potency of 153N-6 for competitively inhibiting [125I]NDP-MSH binding.
NDP-MSH Binding (binding) of associated with melanocortin 1 receptor and potency
8) Confidence 0.01 Published 1996 Journal Peptides Section Abstract Doc Link 8801544 Disease Relevance 0 Pain Relevance 0.30
The results indicated that 153N-6 peptide can competitively inhibit [125I]NDP-MSH binding from all the receptor subtypes investigated.
NDP-MSH Binding (binding) of
9) Confidence 0.01 Published 1996 Journal Peptides Section Abstract Doc Link 8801544 Disease Relevance 0 Pain Relevance 0.27
The relative potency order of 153N-6 for inhibiting [125I]NDP-MSH binding was MC1R (Ki 955 +/- 35.7 nM) = MC4R (Ki 1151 +/- 106 nM) > MC3R (Ki 3229 +/- 637 nM) > MC5R (Ki 6286 +/- 462 nM), which is different than the potency order of either NDP-MSH or alpha-MSH.
NDP-MSH Binding (binding) of associated with potency
10) Confidence 0.01 Published 1996 Journal Peptides Section Abstract Doc Link 8801544 Disease Relevance 0 Pain Relevance 0.29

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox